Patents by Inventor Arlene H. Sharpe

Arlene H. Sharpe has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS OF TREATING CANCER USING LSD1 INHIBITORS IN COMBINATION WITH IMMUNOTHERAPY
    Publication number: 20240018242
    Abstract: Provided herein are methods of treating cancer using LSD1 inhibitors in combination with immunotherapy.
    Type: Application
    Filed: May 17, 2023
    Publication date: January 18, 2024
    Inventors: Yang Shi, Wanqiang Sheng, Arlene H. Sharpe, Martin W. LaFleur
  • METHODS OF TREATING AN INDIVIDUAL THAT HAS FAILED AN ANTI-PD-1/ANTI-PD-L1 THERAPY
    Publication number: 20230340124
    Abstract: Provided herein are methods of treating cancer in an individual that has failed an anti-PD1/PD-L1 therapy, comprising selecting an individual that has failed a prior anti-PD1/PD-L1 therapy; and administering to the individual a first agent that blocks or disrupts PD-L2, RGMb, or a combination thereof, and a second agent that blocks or disrupts PD-L1, PD-1 or a combination thereof. Also provided herein are kits and therapeutic compositions for use in the methods described herein.
    Type: Application
    Filed: September 16, 2021
    Publication date: October 26, 2023
    Inventors: Gordon J. Freeman, Francesca S. Gazzaniga, Joon Seok Park, Arlene H. Sharpe, Dennis L. Kasper
  • ANTI-PHOSPHOTYROSINYLATED PROGRAMMED DEATH 1 (PD-1) MONOCLONAL ANTIBODIES, METHODS OF MAKING AND METHODS OF USING THEREOF
    Publication number: 20230331847
    Abstract: The present invention is based, in part, on the discovery of monoclonal and polyclonal antibodies that specifically bind to phosphorylated PD-1, as well as immunoglobulins, polypeptides, nucleic acids thereof, and methods of using such antibodies for diagnostic, prognostic, and therapeutic purposes.
    Type: Application
    Filed: September 22, 2022
    Publication date: October 19, 2023
    Inventors: Gordon J. Freeman, Vassiliki A. Boussiotis, Xia Bu, Vikram R. Juneja, Arlene H. Sharpe, Nikolaos Patsoukis, Jessica Weaver, Laura Strauss
  • Methods of treating cancer using LSD1 inhibitors in combination with immunotherapy
    Patent number: 11685782
    Abstract: Provided herein are methods of treating cancer using LSD1 inhibitors in combination with immunotherapy.
    Type: Grant
    Filed: October 23, 2018
    Date of Patent: June 27, 2023
    Assignees: Children's Medical Center Corporation, President & Fellows of Harvard College
    Inventors: Yang Shi, Wanqiang Sheng, Arlene H. Sharpe, Martin W. LaFleur
  • Anti-phosphotyrosinylated programmed death 1 (PD-1) monoclonal antibodies, methods of making and methods of using thereof
    Patent number: 11492403
    Abstract: The present invention is based, in part, on the discovery of monoclonal and polyclonal antibodies that specifically bind to phosphorylated PD-1, as well as immunoglobulins, polypeptides, nucleic acids thereof, and methods of using such antibodies for diagnostic, prognostic, and therapeutic purposes.
    Type: Grant
    Filed: April 20, 2018
    Date of Patent: November 8, 2022
    Assignees: Dana-Farber Cancer Institute, Inc., Beth Israel Deaconess Medical Center, President and Fellows of Harvard College
    Inventors: Gordon J. Freeman, Vassiliki A. Boussiotis, Xia Bu, Vikram R. Juneja, Arlene H. Sharpe, Nikolaos Patsoukis, Jessica Weaver, Laura Strauss
  • METHODS AND COMPOSITIONS FOR TREATING CANCER
    Publication number: 20220213212
    Abstract: Provided herein are methods and compositions for treating cancer or a tumor in a subject by administering to the subject a first agent that disrupts the interaction between PD-L2/RGMb and a second agent that disrupts the interaction between PD-1/PD-L1. The subject may have dysbiosis and/or be nonresponsive to immune checkpoint therapy.
    Type: Application
    Filed: March 23, 2022
    Publication date: July 7, 2022
    Inventors: Francesca S. Gazzaniga, Joon Seok Park, Arlene H. Sharpe, Dennis Kasper
  • METHODS AND COMPOSITIONS FOR TREATING CANCER
    Publication number: 20220204604
    Abstract: Provided herein are methods and compositions for treating cancer or a tumor in a subject by administering to the subject a first agent that disrupts the interaction between PD-L2/RGMb and a second agent that disrupts the interaction between PD-1/PD-L1. The subject may have dysbiosis and/or be nonresponsive to immune checkpoint therapy.
    Type: Application
    Filed: September 13, 2021
    Publication date: June 30, 2022
    Inventors: Francesca S. Gazzaniga, Joon Seok Park, Arlene H. Sharpe, Dennis Kasper
  • Agents that modulate immune cell activation and methods of use thereof
    Patent number: 11359020
    Abstract: The present invention relates to compositions and methods for the immunomodulation mediated by the interaction of PD-L2 and RGMb.
    Type: Grant
    Filed: September 16, 2019
    Date of Patent: June 14, 2022
    Assignees: Dana-Farber Cancer Institute, Inc., President and Fellows of Harvard College, Children's Medical Center Corporation
    Inventors: Gordon J. Freeman, Arlene H. Sharpe, Yanping Xiao, Loise Francisco, Rosemarie Dekruyff, Dale Umetsu
  • MODULATING PTPN2 TO INCREASE IMMUNE RESPONSES AND PERTURBING GENE EXPRESSION IN HEMATOPOIETIC STEM CELL LINEAGES
    Publication number: 20220081691
    Abstract: The present invention relates, in part, to methods of treating a subject with a condition that would benefit from an increased immune response comprising administering to the subject a therapeutically effective amount of an agent that inhibits PTPN2. The present invention also provides methods and compositions for perturbing gene expression in hematopoietic cell lineages.
    Type: Application
    Filed: August 5, 2019
    Publication date: March 17, 2022
    Inventors: William N. Haining, Arlene H. Sharpe, Martin Lafleur, Thao Nguyen
  • METHODS OF REDUCING LIVER PD-1-EXPRESSING CD8+ T CELLS USING PD-1 FC FUSION PROTEINS THAT BIND FC RECEPTORS
    Publication number: 20220041726
    Abstract: The present invention relates to methods of reducing liver PD-1-expressing CD8+ T cells using PD-1 Fc fusion proteins that bind Fc receptors, as well as diagnostic, prognostic, therapeutic methods and compositions related thereto.
    Type: Application
    Filed: August 20, 2021
    Publication date: February 10, 2022
    Inventors: Gordon J. Freeman, Rafi Ahmed, Arlene H. Sharpe, Masao Hashimoto, Hyun T. Jin
  • IDENTIFICATION OF GUT BACTERIA THAT PROMOTE AN ANTI-TUMOR RESPONSE TO IMMUNOTHERAPY
    Publication number: 20220023359
    Abstract: In certain aspects, provided herein are methods and compositions for treating or preventing cancer in a subject by conjointly administering to a subject a composition comprising a bacterium (e.g., a bacterium species or strain disclosed herein) and an immunotherapeutic agent.
    Type: Application
    Filed: December 6, 2019
    Publication date: January 27, 2022
    Inventors: Francesca S. Gazzaniga, Dennis Kasper, Joon Seok Park, Arlene H. Sharpe
  • COMPOSITIONS AND METHODS FOR MODULATING AN IMMUNE RESPONSE
    Publication number: 20220010275
    Abstract: The invention provides methods of modulating follicular regulatory T (TFR) cell-mediated immune responses and the use of those methods in the treatment of diseases or conditions such as viral, bacterial, pathogenic, or fungal infections or cancer. Such methods provide for boosting of antibody production through the use of IL-21 to overcome TFR cell suppression of antibody production.
    Type: Application
    Filed: May 7, 2021
    Publication date: January 13, 2022
    Inventors: Arlene H. Sharpe, Peter T. Sage
  • Regulatory T cell PD-1 modulation for regulating T cell effector immune responses
    Patent number: 11207393
    Abstract: The present invention is based, in part, on the identification of methods of modulating PD-1 expression and/or activity in regulatory T cells (Tregs) to thereby regulate effector immune responses in effector T cells (Teffs).
    Type: Grant
    Filed: October 14, 2016
    Date of Patent: December 28, 2021
    Assignees: President and Fellows of Harvard College, The Brigham and Women's Hospital, Inc., Dana-Farber Cancer Institute, Inc.
    Inventors: Arlene H. Sharpe, Gordon J. Freeman, Loise M. Francisco, Peter T. Sage, Sun J. Lee, Scott B. Lovitch, Vikram R. Juneja, Catherine L. Tan
  • Methods of reducing liver PD-1-expressing CD8+ T cells using PD-1 Fc fusion proteins that bind Fc receptors
    Patent number: 11124569
    Abstract: The present invention relates to methods of reducing liver PD-1-expressing CD8+ T cells using PD-1 Fc fusion proteins that bind Fc receptors, as well as diagnostic, prognostic, therapeutic methods and compositions related thereto.
    Type: Grant
    Filed: September 16, 2016
    Date of Patent: September 21, 2021
    Assignees: Dana-Farber Cancer Institute, Inc., President And Fellows Of Harvard College, Emory University
    Inventors: Gordon J. Freeman, Rafi Ahmed, Arlene H. Sharpe, Masao Hashimoto, Hyun T. Jin
  • Compositions and methods for modulating an immune response
    Patent number: 11028364
    Abstract: The invention provides methods of modulating follicular regulatory T (TFR) cell-mediated immune responses and the use of those methods in the treatment of diseases or conditions such as viral, bacterial, pathogenic, or fungal infections or cancer. Such methods provide for boosting of antibody production through the use of IL-21 to overcome TFR cell suppression of antibody production.
    Type: Grant
    Filed: November 23, 2016
    Date of Patent: June 8, 2021
    Assignee: President and Fellows of Harvard College
    Inventors: Peter T. Sage, Arlene H. Sharpe
  • Single agent anti-PD-L1 and PD-L2 dual binding antibodies and methods of use
    Patent number: 10934353
    Abstract: The present invention is based, in part, on the identification of novel antibodies that have binding affinity for both PD-L1 and PD-L2 and methods of using same.
    Type: Grant
    Filed: November 7, 2017
    Date of Patent: March 2, 2021
    Assignees: Dana-Farber Cancer Institute, Inc., President and Fellows of Harvard College
    Inventors: Gordon J. Freeman, Arlene H. Sharpe
  • Compositions and methods for identification, assessment, prevention, and treatment of T-cell exhaustion using CD39 biomarkers and modulators
    Patent number: 10927410
    Abstract: The present invention is based on the identification, of compositions and methods for the identification, assessment, prevention, and treatment of T-cell exhaustion using CD39 biomarkers and modulators.
    Type: Grant
    Filed: October 16, 2015
    Date of Patent: February 23, 2021
    Assignees: Dana-Farber Cancer Institute, Inc., President and Fellows of Harvard College
    Inventors: William N. Haining, Arlene H. Sharpe, Jernej Godec
  • METHODS OF TREATING CANCER USING LSD1 INHIBITORS IN COMBINATION WITH IMMUNOTHERAPY
    Publication number: 20200255527
    Abstract: Provided herein are methods of treating cancer using LSD1 inhibitors in combination with immunotherapy.
    Type: Application
    Filed: October 23, 2018
    Publication date: August 13, 2020
    Inventors: Yang Shi, Wanqiang Sheng, Arlene H. Sharpe, Martin W. LaFleur
  • Methods and compositions for perturbing gene expression in hematopoietic stem cell lineages in vivo
    Patent number: 10653123
    Abstract: The invention provides methods and compositions for perturbing gene expression in hematopoietic cell lineages in vivo.
    Type: Grant
    Filed: May 27, 2015
    Date of Patent: May 19, 2020
    Assignees: Dana-Farber Cancer Institute, Inc., President and Fellows of Harvard College
    Inventors: William N. Haining, Arlene H. Sharpe, Jernej Godec
  • ANTI-PHOSPHOTYROSINYLATED PD-1 ANTIBODIES AND USES THEREOF
    Publication number: 20200115452
    Abstract: The present invention is based, in part, on the discovery of monoclonal and polyclonal antibodies that specifically bind to phosphorylated PD-1, as well as immunoglobulins, polypeptides, nucleic acids thereof, and methods of using such antibodies for diagnostic, prognostic, and therapeutic purposes.
    Type: Application
    Filed: April 20, 2018
    Publication date: April 16, 2020
    Inventors: Gordon J. Freeman, Vassiliki A. Boussiotis, Xia Bu, Vikram R. Juneja, Arlene H. Sharpe, Nikolaos Patsoukis, Jessica Weaver, Laura Straus